India's Bajaj Healthcare rises as insomnia pill trial gets regulatory nod
06/10/2025 05:45
** Shares of Bajaj Healthcare BAJH.NS rise about 3% to 498 rupees
** The pharmaceutical co's insomnia pill Suvorexant receives SEC (subject expert committees) panel under India's drug regulator CDSCO nod for phase three clinical trials
** Phase three trial representing the final and most crucial step before regulatory submission- BAJH
** Stock down nearly 13% YTD
(Reporting by Komal Salecha)
((Komal@thomsonreuters.com;))
Recent news on Bajaj Healthcare
See all newsBrief: Bajaj Healthcare Ltd Posts March-Quarter Loss 228.5 Million Rupees
Brief: Bajaj Healthcare Posts Dec-Quarter Profit Of 156.7 Million Rupees
Brief: Bajaj Healthcare Receives CDSCO Approval For Suvorexant Tablets Trial
India's Bajaj Healthcare rises as insomnia pill trial gets regulatory nod
Brief: Bajaj Healthcare Posts June-Quarter Profit Of 118.3 Million Rupees